伏立康唑药代动力学与CYP2C19基因多态性:病例报告与文献综述
本文报告一例肾移植患者背部无外伤性足放线菌足菌肿,接受伏立康唑治疗但血药浓度持续不达标。药代动力学分析显示伏立康唑半衰期缩短,药物基因组学检测发现CYP2C19 *1/*17基因型(快代谢型)。提示CYP2C19多态性显著影响伏立康唑代谢,基因分型结合TDM有助于个体化治疗。
要点
- CYP2C19快代谢型患者伏立康唑血药浓度可能持续不达标
- 伏立康唑治疗失败风险与CYP2C19基因型相关
- 基因分型联合TDM可优化抗真菌个体化治疗
核心结论
- CYP2C19多态性显著影响伏立康唑代谢,快代谢型患者药物暴露低于慢代谢型。
- 基因分型可能有助于指导剂量调整、预测药物相互作用并提高疗效同时减少不良反应。
研究设计与样本
- 病例报告与文献综述:一例肾移植患者背部无外伤性足放线菌足菌肿,接受手术切除及伏立康唑治疗。
- 进行了药代动力学和药物基因组学检测以评估伏立康唑血药浓度持续不达标的原因。
主要发现
- 患者伏立康唑负荷剂量为400 mg(6 mg/kg)每12小时一次(第1天),随后200 mg每12小时一次(4 mg/kg每日两次),但血药浓度持续不达标。
- 药代动力学分析显示伏立康唑半衰期缩短。
- 药物基因组学检测发现CYP2C19 *1/*17基因型,提示快代谢型,导致药物代谢加速、血药浓度低及治疗失败和疾病进展风险增加。
关键数值与推荐
- 推荐替代伏立康唑的药物包括艾沙康唑、脂质体两性霉素B或泊沙康唑,这些药物不依赖CYP2C19代谢。
- CYP2C19慢代谢型患者相比快代谢型患者有更高的药物暴露。
临床怎么用
- 对于伏立康唑治疗的患者,尤其是血药浓度不达标时,应考虑CYP2C19基因分型检测。
- 整合药物基因组学检测与治疗药物监测(TDM)可增强复杂临床场景中抗真菌治疗和预防的个体化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Scedosporium apiospermum is an opportunistic fungal pathogen that causes various infections in immunocompromised patients. Voriconazole is the first-line treatment; however, its clinical use is often challenging due to complex pharmacokinetics and significant interpatient variability, primarily driven by polymorphisms in the CYP450 (CYP2C19) enzymes. These genetic variations affect drug metabolism, resulting in suboptimal drug levels or increased toxicity. We present a case of atraumatic localized Scedosporium apiospermum mycetoma on the back of a patient with a renal transplant. The patient underwent surgical excision and was initiated on voriconazole with a loading dose of 400 mg (6 mg/kg) every 12 h on day one, followed by 200 mg every 12 h (4 mg/kg twice daily). Despite dose adjustments, voriconazole serum levels remained persistently sub-therapeutic. Pharmacokinetic and pharmacogenetic studies were conducted for further evaluation. Pharmacokinetic analysis revealed a shortened voriconazole half-life. Pharmacogenetic testing identified a CYP2C19 *1/*17 genotype, indicating a rapid metaboliser phenotype. This resulted in accelerated drug metabolism, low serum levels and an increased risk of treatment failure and disease progression. Alternative agents to voriconazole, independent of CYP2C19 (isavuconazole, liposomal amphotericin B or posaconazole) were recommended for current and future therapy. Pharmacogenetic and pharmacokinetic testing may play a role in optimizing antifungal therapy. CYP2C19 polymorphisms significantly affect voriconazole metabolism. Patients that are poor metabolisers have greater drug exposure compared with rapid metabolisers. Genotyping may help guide dosage adjustments, predict potential drug interactions and improve treatment efficacy whilst reducing adverse effects. The integration of pharmacogenomic testing, along with therapeutic drug monitoring (TDM), can enhance individualized therapy for both antifungal treatment and prophylaxis in complex clinical scenarios.
引用
- Ahmer S, Bui J, Sivabalan P, et al. Navigating therapeutic challenges: Voriconazole pharmacokinetics and CYP2C19 genetic polymorphism-A case report and literature review. Br J Clin Pharmacol. 2025. PMID: 41168950. doi:10.1002/bcp.70320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。